依达拉奉右莰醇注射用浓溶液联合丁苯酞对急性脑梗死患者神经功能及日常生活能力的改善作用

The improvement effect of edaravone and dexborneol concentrated solutio combined with butylphthalein on neurological function and daily living ability in patients with acute cerebral infarction

目的探究依达拉奉右莰醇注射用浓溶液联合丁苯酞对急性脑梗死患者神经功能及日常生活能力的改善作用。方法选取2019年7月至2022年1月菏泽市立医院收治的70例急性脑梗死患者作为研究对象,采用随机抽签法分为对照组与观察组,每组35例。对照组给予依达拉奉右莰醇注射用浓溶液治疗,观察组给予依达拉奉右莰醇注射用浓溶液联合丁苯酞治疗。比较两组临床疗效、实验室检查结果[丙二醛(MDA)、C反应蛋白(CRP)、基质金属蛋白酶-9(MMP-9)、超氧化物歧化酶(SOD)]、神经功能缺损程度[美国国立卫生研究院卒中量表(NIHSS)]及日常生活活动能力[日常生活活动能力(ADL)]、用药安全性。结果观察组临床总有效率为94.29%,高于对照组的77.14%,差异有统计学意义(P<0.05)。用药2周后,观察组血清MDA、CRP及MMP-9水平均低于对照组,血清SOD水平高于对照组,差异有统计学意义(P<0.05)。用药2周后,观察组NIHSS评分低于对照组,ADL评分高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论依达拉奉右莰醇注射用浓溶液联合丁苯酞用于急性脑梗死患者的治疗效果较理想,安全可靠,可减轻机体炎症反应、氧化应激反应,促进神经功能修复,提高日常生活活动能力,值得临床推广应用。

Objective To investigate the effect of edaravone and dexborneol concentrated solutio combined with butylphthalide on the improvement of neurological function and daily living ability in patients with acute cerebral infarction.Methods 70 patients with acute cerebral infarction admitted to Heze Municipal Hospital from July 2019 to January 2022 were selected as the research subjects,and they were divided into the control group and the observation group according to randow drawing,with 35 cases in each group.The control group was treated with edaravone and dexborneol concentrated solutio,and the observation group were treated with edaravone and dexborneol concentrated solutio combined with bu-tylphthalide.The clinical effective,laboratory test results(serum malondialdehyde[MDA],C-reactive protein[CRP],matrix metalloproteinase-9[MMP-9],superoxide dismutase[SOD]),degree of neurological impairment(National Institutes of Health Stroke Scale[NIHSS]),ability of daily liv-ing(activity of daily living[ADL])and drug safety were compared between the two groups.Results The total clinical effective rate in the observation group was 94.29%,which was higher than 77.14%in the control group,the difference was statistically significant(P<0.05).After 2 weeks of treatment,the serum levels of MDA,CRP and MMP-9 in the observation group were lower than those in the control group,the serum SOD level in the observation group was higher than that in the control group,the differences were statistically significant(P<0.05).After 2 weeks of treatment,the NIHSS score in the observation group was lower than that in the control group,the ADL score in the observation group was higher than that in the control group,the differences were statistically significant(P<0.05).there was no significant difference in the total incidence of adverse reactions between the two groups.Conclusion The edaravone and dexborneol concentrated solutio combined with butylphthalide for patients with acute cerebral infarction is ideal,safe and reliable,superior to single drug,which can reduce the inflammatory reaction and oxidative stress reaction of the body,promote the repair of neural function,and enable patients to resume daily life as soon as possible,which is worthy of promotion and application.